India's First mRNA Vaccine
  • Home
  • WHO WE ARE
    • GENNOVA BIO
    • OUR STRENGTHS
  • ABOUT GEMCOVAC
    • STORY OF mRNA VACCINES
    • TECHNICAL DETAILS
  • MEDIA
    • PRESS COVERAGE
  • CONTACT US
    • SALES
    • HEALTHCARE PROFESSIONALS
    • HOSPITAL/INSTITUTION
    • MEDIA AND PRESS
  • More
    • Home
    • WHO WE ARE
      • GENNOVA BIO
      • OUR STRENGTHS
    • ABOUT GEMCOVAC
      • STORY OF mRNA VACCINES
      • TECHNICAL DETAILS
    • MEDIA
      • PRESS COVERAGE
    • CONTACT US
      • SALES
      • HEALTHCARE PROFESSIONALS
      • HOSPITAL/INSTITUTION
      • MEDIA AND PRESS
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

India's First mRNA Vaccine

Signed in as:

filler@godaddy.com

  • Home
  • WHO WE ARE
    • GENNOVA BIO
    • OUR STRENGTHS
  • ABOUT GEMCOVAC
    • STORY OF mRNA VACCINES
    • TECHNICAL DETAILS
  • MEDIA
    • PRESS COVERAGE
  • CONTACT US
    • SALES
    • HEALTHCARE PROFESSIONALS
    • HOSPITAL/INSTITUTION
    • MEDIA AND PRESS

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

WHO WE ARE

STATE OF THE ART R&D FACILITIES

WORLD CLASS MANUFACTURING FACILITY

WORLD CLASS MANUFACTURING FACILITY

With over 40,000 sq.ft. of space dedicated to research and development of biologics and therapeutics 

WORLD CLASS MANUFACTURING FACILITY

WORLD CLASS MANUFACTURING FACILITY

WORLD CLASS MANUFACTURING FACILITY

Incorporating advanced cGMP manufacturing facility to scale up production

GLOBAL PRESENCE

WORLD CLASS MANUFACTURING FACILITY

GLOBAL PRESENCE

Our innovations across various technologies are available globally     

INTRODUCTION

Gennova Biopharmaceuticals Limited, headquartered in Pune, India, is a biotechnology company dedicated to developing, producing, and commercializing biotherapeutics to address life-threatening diseases across various indications.

TRANSFORMING HEALTHCARE

Gennova is transforming healthcare by creating efficient and effective solutions for manufacturing and successfully commercializing bio-therapeutics across cardiovascular, neurology, nephrology, and oncology segments. Incorporating recombinant DNA technologies and innovative bio-manufacturing practices The company manufactures its recombinant products using bacterial, yeast, and mammalian-based expression platforms and has developed deep expertise in perfusion-based continuous manufacturing technologies. 


To date, Gennova has commercialized seven products; 5 biosimilars, one generic, and one pioneering – ‘first in the world’ product. Gennova has also developed an mRNA-based platform technology for COVID-19 vaccines.

Copyright © 2023 Gennova Biopharmaceuticals Limited - All Rights Reserved.

  • Privacy Policy
  • Terms and Conditions

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept